AKT1 and colorectal cancer: The activation of PI3K/AKT as an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway by EGFR and MEK inhibitors in KRAS-mutant colorectal cancer has also been reported and is linked to drug resistance and disease recurrence [31].